TITLE: Identification and Genomic Assessment of Daptomycin-, Linezolid-, Vancomycin-resistant Enterococcus faecium During Protracted Infection RUNNING TITLE: Evaluation of Multidrug Resistant Enterococcus faecium During Protracted Infection AUTHORS: Nathan B. Pincus^{1*}, Tejas Joshi^{1*}, Samuel W.M. Gatesy², Omar Al-Heeti², W. Justin Moore³, and Kelly E. R. Bachta^{2#} **AFFILIATIONS:** ¹ Feinberg School of Medicine, Northwestern University, Chicago, Illinois ² Division of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, Illinois ³ Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois *Co-first authors *Corresponding author: Kelly E. R. Bachta, kelly.bachta@northwestern.edu

25 ABSTRACT

26 Linezolid and daptomycin resistance among *Enterococccus faecium* (*Efm*) isolates, while rare, is a major 27 challenge for clinicians who are often limited to broad-spectrum or combination antibiotic therapies for 28 management. Combination therapy with a beta-lactam has been reported, but limited clinical evidence 29 exists to support its use. We describe the clinical management of a prolonged Efm intraabdominal (IA) 30 infection and subsequent bacteremia, along with observed multidrug resistance development and use of 31 serial whole genome sequencing to better understand resistance mechanisms. Combination 32 antimicrobial therapy with daptomycin (DAP) and ceftaroline (CPT) was used to treat the patient's 33 catheter-associated daptomycin-, linezolid-, vancomycin-resistant Efm (DLVRE) bloodstream infection. In vitro antimicrobial testing of this DLVRE revealed only minor synergy between daptomycin and 34 35 ceftaroline; However, the patient's bacteremia cleared following initiation of combination therapy in 36 conjunction with catheter removal. Sequencing of the patient's DLVRE revealed multiple genomic 37 mutations which explain both linezolid and daptomycin resistance and the presence of a plasmid 38 containing known resistance determinants for vancomycin. Daptomycin resistance was attributed to the 39 presence of chromosomal mutations in *liaS* (Thr120Ala), *liaR* (Trp73Cys), and *cls* (Asp13Ile), while linezolid resistance was attributed to the presence of the G2576T variant allele in some of 23S rRNA gene copies. 40 41 Sequential whole genome sequencing of two additional bacterial isolates from the same patient revealed 42 protracted colonization with a single DLVRE clone and suggested the development of bacterial 43 subpopulations. Pairing clinical isolate susceptibilities with whole genome sequencing should be encouraged in clinical practice to better inform antimicrobial management in cases of multidrug 44 45 resistance.

46

47 KEYWORDS

48 \

Vancomycin-resistant Enterococcus faecium, daptomycin-resistance, linezolid-resistance

49 **INTRODUCTION**

50 Multidrug resistant Enterococcus faecium (Efm) is an important cause of nosocomial infections including 51 bacteremia, intraabdominal (IA) and urinary tract infections (UTIs). The incidence of enterococcal 52 infections has increased steadily since the late 1970s (1) and enterococci are second only to Escherichia 53 coli as a cause of nosocomial infection (2). In disease states, enterococci are believed to escape from the 54 gastrointestinal (GI) tract, where they are natural colonizers and an important part of the GI microbiota 55 (3). As GI tract residents, enterococci are frequently exposed to serial courses of antibiotics and have a 56 remarkable ability to persist in part due to the plasticity of their genome (4). Antimicrobial resistance 57 (AMR) arises through both genomic mutation and acquisition of mobile elements such as transposons and 58 plasmids (5). Most enterococci demonstrate low-level intrinsic resistance to beta lactam antibiotics, 59 moderate resistance to aminogly cosides and high resistance to most cephalosporins and clindamycin (6). 60 Natural ampicillin resistance in *Efm* is largely attributed to penicillin-binding protein (PBP5) encoded by 61 the bacterial chromosome, with variation in degree of resistance due to variable gene expression (7, 8) 62 and the presence of a low-affinity allele associated with increased levels of resistance in the dominant 63 hospital-associated Efm clade (1, 9, 10). Vancomycin resistance is driven by replacement of the terminal 64 D-alanine residue of peptidoglycan precursors with either D-lactate or D-serine (3, 11). These altered 65 peptidoglycan fragments are generated through expression of multiple gene clusters (van operons) which 66 can be present on either the chromosome or transferable mobile plasmids (11).

Treatment of VRE often requires the use of newer antimicrobial agents including linezolid (LZD) and daptomycin (DAP) (12, 13). Though overall resistance remains rare (<1% for linezolid and <2% for daptomycin) (14, 15), resistance to both agents emerged shortly after these antibiotics were clinically introduced and is rising steadily (12, 15-19). Specifically, linezolid resistance is mediated by both chromosomal mutations and gene acquisition. Resistance to linezolid is linked to mutations in 23S ribosomal RNA genes and acquisition of plasmid-borne genes *cfr* and *optrA* encoding a ribosomal

methyltransferase and an ATP-binding cassette transporter, respectively (15). Enterococcal resistance to daptomycin is more common in *Efm* than *E. faecalis* (1, 14), and resistance has been linked to mutations in two major groups of genes. The first (*liaFSR* and *yycFGHIJ*) encodes regulatory pathways that coordinate the stress response of the bacterial cell envelope. The second encodes enzymes that metabolize phospholipids, including glycerophosphoryl diester phosphodiesterase (*gdpD*) and cardiolipin synthetase (*cls*) (20, 21). The understanding of both linezolid and daptomycin resistance in enterococci continues to evolve (15, 20, 21).

80 Although they represent <1% of all enterococcal infections, the prevalence of daptomycin-, 81 linezolid-, and vancomycin-resistant Efm (DLVRE) is increasing (14, 15, 22). Risk factors associated with 82 the development of DLVRE include neutropenia, invasive procedures and cumulative antibiotic exposure, 83 notably exposure to daptomycin, within the past year (23, 24). There are limited data on efficacious 84 treatments for such infections. Combination therapy of daptomycin and a beta lactam antibiotic is 85 thought to act synergistically to sensitize the bacterial cell membrane and improve the penetration of 86 daptomycin (25). This combination is being explored for treatment (26, 27). In vitro studies with VRE 87 revealed that ceftaroline (CPT) increased the bactericidal activity of daptomycin and lowered the 88 daptomycin minimal inhibitory concentration (MIC) when co-administered (27-30). However, data are 89 limited on the impact of dual antimicrobial therapy on clinical outcomes of patients with DLVRE infections. 90 Here, we report successful treatment of DLVRE catheter-associated bloodstream infection 91 (CLABSI) in the setting of protracted IA abscess. We applied whole genome sequencing to characterize 92 the genetic changes underlying emerging linezolid and daptomycin resistance in this case of persistent 93 infection.

94

95 METHODS

96 Antimicrobial Resistance Testing

97 Antimicrobial resistance testing was performed at Northwestern Memorial Hospital and Northwestern 98 University using the Vitek2 platform (bioMerieux) and Epsilometer testing (E- test). Additional synergy 99 testing was performed on Mueller Hinton II (MHII) agar using E-test strips (Lisofilchem s.r.l). Briefly, 100 bacteria were grown overnight at 37°C on blood agar plates. A suspension at optical density 600 (OD 600) 101 of 0.08 to 0.1 was created by resuspending bacterial colonies in phosphate buffered saline (PBS). This 102 suspension was subsequently confluently spread across the surface of a MHII agar plate. Plates were 103 dried for five minutes and then a single DAP E-test strip was placed in the center of the plate and incubated 104 for ten minutes. This DAP E-test strip was then removed and saved. In the same location and orientation 105 as the DAP E-test, a CPT E-test strip was placed and the original DAP E-test strip replaced directly on-top 106 (31). DAP and CPT single E-test controls were laid side-by-side on the same plates. The plates were 107 incubated at 37°C for 24 hours, and the minimal inhibitor concentrations (MIC) were interpreted.

108

109 Whole genome sequencing and genome assembly

110 Genomic DNA from Isolate 3 was isolated from a single colony grown overnight in 5 mL of tryptic soy broth 111 using the Promega Maxwell 16 instrument. A short-read sequencing library was prepared with a plexWell[™] 96 kit (seqWell), and sequencing was performed on an Illumina MiSeq with a v3 reagent kit 112 113 yielding 709,596 301 bp paired-end reads totaling 427 Mbp. Illumina reads were quality trimmed using 114 Trimmomatic v0.36 (32), resulting in 450,275 paired-end reads totaling 179 Mbp of sequence for 115 approximate genomic coverage of 60-fold. Long-read sequencing was performed on the MinION platform 116 with a FLO-MIN106 flow cell after library preparation with an Oxford Nanopore SQK-LSK109 ligation 117 sequencing kit. Base calling and read-quality filtering was performed using Guppy v3.4.5 with the R9.4.1 118 high-accuracy model, yielding 248,837 reads totaling 1,339 Mbp. Using Filtlong v0.2.0, Nanopore reads 119 were filtered to retain the best 95% of sequence with a minimum read length of 1000 bp, yielding 196,162 120 reads totaling 1,272 Mbp of sequence for an approximate coverage of 424-fold. Hybrid genome assembly

was performed based on trimmed Illumina reads and filtered nanopore reads using Unicycler v0.4.8 (33)
with default settings. The resulting complete genome was annotated using the NCBI Prokaryotic Genome
Annotation Pipeline v5.3 (34). *In silico* sequence typing was performed by comparing our existing
genomic sequences to *Efm* allele sequences and MLST profiles obtained from the PubMLST database (35).
Isolate 3 plasmid replicons were identified using PlasmidFinder v2.1 (36) and compared to previouslydescribed plasmids by BLAST search against *Enterococcus* sequences in the NCBI nt database.

127 Genomic DNA preparation and short-read sequencing library preparation for Isolates 4 and 5 were 128 performed as described above. Sequencing was performed on an Illumina NovaSeq instrument yielding 129 150 bp paired-end reads totaling 162 Mbp for Isolate 4 and 316 Mbp for Isolate 5. Read trimming was 130 performed as described above yielding 118 Mbp of sequence for Isolate 4 for an approximate coverage of 131 39-fold and 233 Mbp of sequence for isolate 5 for an approximate coverage of 78-fold. Draft genomes of 132 Isolate 4 and 5 were assembled using SPAdes v3.9.1 with careful and automatic read coverage cutoff 133 options (37) and filtered to remove contigs less than 200 bp or 5-fold mean coverage. Draft genomes 134 were annotated using the NCBI Prokaryotic Genome Annotation Pipeline v5.3 (34). In silico sequence 135 typing was performed as described above.

136

137 Antimicrobial resistance gene identification

138 Known single nucleotide variants (SNVs) and acquired genes associated with AMR were identified in 139 assembled genomes using AMRFinderPlus v3.10.16 (38) and ResFinder v4.1 (39). Illumina reads were 140 screened for the presence of linezolid resistance mechanisms, including 23S rRNA gene variations and 141 acquired genes, using LRE-Finder v1.0 (40).

143 Pairwise genome comparisons

144	Isolates 4 and 5 were aligned to the Isolate 3 complete genome and SNVs between strains were identified
145	as previously described (41). Briefly, trimmed Illumina reads were aligned to the Isolate 3 chromosome
146	and plasmids using BWA v0.7.15 (https://arxiv.org/abs/1303.3997v2) and the resulting alignments sorted
147	and indexed using samtools v0.1.19-44428cd (42). SNV calling from these alignments was performed
148	using bcftools_filter.pl (<u>https://github.com/egonozer/bcftools_filter</u>). To better understand the genetic
149	context of missing AMR genes in the Isolate 4 draft genome, Isolate 4 and 5 draft genome contigs were
150	aligned to plasmid 3 of Isolate 3 using BRIG v0.95 (43).

151

152 Data availability

Sequencing and genome assemblies have been deposited to NCBI under BioProject accession number PRJNA787599, with Isolate 3 termed NMVRE-001 (SAMN23828484), Isolate 4 termed NMVRE-002 (SAMN23828912), and Isolate 5 termed NMVRE-003 (SAMN23828937). Reads are available under SRA accessions SRR17230443-SRR17230446. Assemblies are available under GenBank accessions GCA_021228615.1, GCA_021364775.1, and GCA_021364755.1.

158

159 **Bioethics Statement**

160 This research study (STU00214816) was submitted for review to the Northwestern University Institutional 161 Review Board and, because of the retrospective nature of this work, was deemed "research that does not 162 involve human subjects". Further IRB review and approval was, therefore, not required. In good faith, 163 the case report was discussed openly with the patient in question and the patient verbally consented to 164 its publication.

166

167 **RESULTS**

168 Case Presentation

169 A middle-aged patient with a history of small bowel obstruction requiring multiple laparoscopic 170 abdominal surgeries presented to our institution for elective incisional hernia repair. The patient 171 underwent lysis of adhesions and small bowel resection with primary anastomosis and mesh closure. The 172 patient's post-operative course was complicated by the development of loculated IA abscesses secondary 173 to an enteric leak at the anastomotic site. A drain was placed into the largest abscess and aspiration 174 cultures were obtained on post-operative day (POD) 10 revealing a polymicrobial abscess including 175 Escherichia coli, Enterococcus faecalis, coagulase-negative Staphylococcus, Streptococcus constellatus, 176 Candida albicans and vancomycin-resistant Efm (Table 1, Isolate 1, VRE). Given an allergy to penicillin, 177 the patient was initially treated with aztreonam and metronidazole. When cultures returned, the patient 178 was transitioned to culture-directed therapy (meropenem, fluconazole and linezolid) for four weeks 179 (Figure 1). At the completion of this course, clinical and radiographic improvement was achieved.

180 Four days after stopping antibiotics (POD 50), the patient developed recurrent abdominal pain 181 and leukocytosis of 26.6K cells/ μ L. Meropenem, fluconazole and daptomycin were initiated. Daptomycin 182 was chosen out of concern for long-term linezolid toxicity. Repeat IA cultures on POD 50 demonstrated a 183 new linezolid resistant-VRE (Table 1, Isolate 2, LVRE). The patient was ultimately treated with intravenous 184 ceftriaxone, fluconazole and daptomycin. On POD 73, following an episode of emesis directly onto an 185 existing right brachial peripherally inserted central catheter (PICC), the patient developed a fever. Blood 186 cultures from the periphery and PICC line both revealed new daptomycin resistant-LVRE (Table 1, Isolate 187 3, DLVRE). The PICC line was removed and blood cultures cleared the following day. Ceftaroline was 188 added when the daptomycin non-susceptibility results became available. After one week of combination

antimicrobial therapy, the patient had radiographic decrease in the size of the IA abscess, resolution of
leukocytosis and reduction of fevers. The patient was discharged home on POD 86 off antibiotics.

191 Five weeks after discharge (POD 122), the patient was readmitted with left lower quadrant (LLQ) 192 abdominal pain and increased drainage from around an abdominal drain site. CT scan revealed an 193 additional abdominal wall fluid collection for which the patient underwent incision and drainage. Again, 194 cultures were polymicrobial growing Klebsiella oxytoca, Enterobacter cloacae, Streptococcus anginosus, 195 E. coli, E. faecalis and DLVRE (Table 1, Isolate 4). The patient was diagnosed with an enterocutaneous 196 fistula and briefly treated with ceftriaxone followed by cefepime. In an effort to spare the patient 197 prolonged courses of broad-spectrum antibiotics and in light of the patient's clinical stability, the patient 198 was discharged home off of all antibiotics on POD 128.

199 The patient was readmitted again on POD 169 following a fall. While hospitalized, the patient 200 developed a new leukocytosis to 16.4K cells/µL, worsening LLQ abdominal tenderness and erythema. An 201 abdominal CT scan demonstrated a new 5.8 cm abscess in the left anterior abdominal wall. The abscess 202 was drained and cultures grew Pseudomonas aeruginosa, K. oxytoca, E. cloacae, C. albicans and DLVRE 203 (Table 1, Isolate 5). The patient received a 10-day course of antimicrobials including cefepime, linezolid, 204 metronidazole and fluconazole. Of note, Isolate 5 was initially reported as susceptible to linezolid (MIC of 205 $2 \mu g/mL$ on VITEK2 platform); However, upon confirmatory testing, Isolate 5 was determined to be 206 resistant to linezolid with an MIC of 12 μ g/mL by E-test (Table 1, Isolate 5). Despite this discrepancy, the 207 patient's clinical status improved as erythema, abdominal tenderness and leukocytosis resolved. After 208 one week of inpatient observation off antibiotics, the patient was discharged home on POD 187. A 209 detailed course of antimicrobial therapy is outlined in Figure 1.

210

211 In vitro synergy testing reveals little synergy between DPT and CPT

Given that the patient's CLABSI was secondary to DLVRE (Isolate 3) leaving limited options for therapy, we chose to empirically start combination therapy with daptomycin and ceftaroline (25-27, 30). We sought to validate our antimicrobial choice *in vitro* by conducting synergy antimicrobial resistance testing (31). Confirmatory testing (E-test) in the laboratory revealed individual MICs to daptomycin of 16 μ g/mL and ceftaroline of 32 μ g/mL. Synergy testing in the experimental laboratory revealed only modest synergy, with the addition of ceftaroline lowering the daptomycin MIC from 16 to 12 μ g/mL (Fig. 2). Addition of ceftaroline did not change the clinical interpretation of daptomycin resistance in Isolate 3 (44).

219

220 Genomic evaluation of antimicrobial resistance in Isolate 3

221 We sought to use genomics to understand the mechanisms behind evolving drug-resistance in our DLVRE 222 isolates. Unfortunately, we did not have access to Isolates 1 and 2 for comparison as they had been 223 previously discarded. Whole genome sequencing of Isolate 3 confirmed the identity of a sequence type 224 (ST) 584 Efm. ST584 is a member of the pandemic clonal complex 17 (CC17) that includes a collection of 225 hospital-acquired Efm sequence types (45-47). The complete genome of Isolate 3 included a single 226 chromosome of 2.8 Mbp and 5 plasmids of lengths 228.3 Kbp (p1), 50.1 Kbp (p2), 40.6 Kbp (p3), 11.9 Kbp 227 (p4), and 1.9 Kbp (p5), respectively. The sequence present in these plasmids was similar to that previously 228 described in Efm plasmids, although present in different configurations. For example, nearly all of the 229 sequence present in plasmids 2 and 4 has been described in substantially larger, previously described 230 plasmids (Supplementary Table S1) reaffirming that *Efm* plasmids are highly modular (48).

Examination of the complete genome of Isolate 3 for known antimicrobial resistance determinants reasonably explained the observed susceptibility pattern (Table 2). Isolate 3 contained the low-affinity penicillin-binding protein 5 allele (*pbp5-R*) found in the *Efm* nosocomial clade, clade A, that is associated with ampicillin resistance (1, 9, 10). On the 40.6kb p3, we identified the presence of a *vanA* operon (Figure 3), explaining the observed vancomycin resistance. The *vanA* operon was flanked by

IS1216 family transposases, consistent with the known presence of *vanA* operons on plasmid-borne *Tn1546*-type transposons (49). Daptomycin resistance was attributed to the presence of chromosomal mutations in *liaS* (Thr120Ala), *liaR* (Trp73Cys) and *cls* (Asp13Ile). Other resistance mechanisms identified included fluoroquinolone resistance mutations, *gyrA* (Ser83Tyr) and *parC* (Ser80Arg), aminoglycoside resistance genes *aac*(6')-1, *aph*(3')-IIIa and *ant*(6)-1a, trimethoprim resistance genes *dfrG* and *dfr*F and tetracycline resistance genes *tetL* and *tetM* (Table 2).

242 The mechanism of linezolid resistance for Isolate 3 was not immediately apparent from interrogation of its complete genome sequence. However, a read-based analysis (40) estimated that 243 244 Isolate 3 contained three copies of the variant G2576T allele in the six copy 23S rRNA gene (48% of aligned 245 reads contained the G2576T variant allele). The absence of these variants in the complete genome was 246 likely an artifact of the assembly method, which used nanopore reads to bridge short-read derived contigs 247 (33), combined with the fact that they were present in only some copies of a multi-copy gene. Variant 248 alleles in the 23S rRNA gene, particularly G2576T, are the most common mechanism of linezolid resistance 249 in Efm (15). The level of linezolid resistance correlates with the number of variant alleles (40, 50). Other 250 determinants associated with acquired linezolid resistance, including the 23S rRNA methyltransferase 251 gene *cfr* and the ATP-binding cassette ABC-F gene *optrA*, were not present in the genome (Table 2).

252

253 Evolution of Enterococcus faecium during protracted infection

Given the patient's repeated admissions and repeated isolation of DLVRE, we chose to perform short-read sequencing on two additional *Efm* Isolates, Isolates 4 and 5. Isolates 4 and 5 were both clonal with Isolate and belonged to the same sequence type, ST584. Isolate 4 had 2 chromosomal SNVs with respect to Isolate 3, while Isolate 5 had 13 chromosomal and 3 p1 SNVs (Supplementary Table S2). All SNVs present in Isolate 5 were previously observed in Isolate 4. While Isolate 4's SNVs were located in intergenic regions, Isolate 5 also contained SNVs in predicted protein coding genes (Supplementary Table S3).

Altogether, these findings strongly suggest persistent infection, or colonization with recurrent infection,
by a specific DLVRE clone.

262 Isolates 4 and 5 contained the same elements associated with resistance to ampicillin, 263 vancomycin, and daptomycin. Similar to Isolate 3, Isolate 4 contained an estimated three copies of the 264 23S rRNA gene containing the G2576T variant allele (56% G2576T), likely leading to observed linezolid 265 resistance. Isolate 5, on the other hand, was estimated to encode two copies of the 23S rRNA gene 266 containing the G2576T variant allele (33% G2576T) (Table 2). As previously stated (40, 50), copy number 267 of the G2576T variant allele correlates with level of resistance, potentially explaining the lower linezolid 268 MIC seen in Isolate 5 (Table 1). There may be other contributing factors given the substantially different 269 MICs between Isolates 3 and 4 despite each possessing the same number of mutant alleles.

270 While the other 4 plasmids were fairly well conserved between Isolates 4 and 5 and Isolate 3, we 271 noted the absence of a substantial portion of p3 in Isolate 4 (Figure 3, Supplementary Table S2), resulting 272 in the loss of resistance genes ermB, ant(6), sat4, and aph(3')-IIIa (Table 2, Figure 3). This deletion of 273 approximately 7.4 Kbp was notably flanked by IS1216 family transposase genes, suggesting that it was 274 located on a mobile element. Interestingly, this sequence was present in Isolate 5 (Figure 3). This implies 275 that multiple subpopulations of this ST584 DLVRE clone developed during our case of protracted infection, 276 as the intact p3 would need to be present on POD 122 when Isolate 4 was collected to be found again in subsequent Isolate 5 on POD 169. 277

278

279 DISCUSSION

In this study, a patient with an IA abscess known to harbor VRE developed DLVRE bacteremia following prolonged sequential treatment with linezolid and daptomycin. Ultimately, the patient experienced an episode of CLABSI secondary to DLVRE. Limited data exist on appropriate antibiotic choice in such

283 challenging clinical situations (16, 24). Based on prior clinical and experimental data (25-27, 29, 30), we 284 elected to use daptomycin in conjunction with ceftaroline for synergy, and the patient achieved a desired 285 clinical response: clearance of blood cultures and diminishing size of an IA abscess. To our knowledge, 286 this is the first case report demonstrating a successful clinical outcome with the use of daptomycin and 287 beta-lactam antimicrobial therapy for CLABSI associated with IA abscesses. In our case, it is difficult to 288 delineate if successful treatment of bacteremia was achieved due to the removal of an infected central 289 line, dual antimicrobial therapy or the combination of both. The generalizability of this combination 290 approach is also limited by our experiences in a single patient. These results point to the need for further 291 evaluation of daptomycin and beta-lactam antimicrobial combination therapy for DLVRE infections in 292 larger clinical studies. This case also highlights the challenges of determining appropriate duration of 293 antibiotics when a polymicrobial abscess persists. Our patient ultimately received a total of 57 days of 294 broad-spectrum antibiotics. Repeat cultures revealed the development of progressive antimicrobial 295 resistance over time and, despite our best stewardship efforts, the patient's symptoms recurred. This 296 outcome underscores the challenges that clinicians face when deploying culture-directed therapy in 297 patients with protracted infectious reservoirs. In settings where complete source control is not 298 achievable, there seems to be no clear answer on antibiotic choice or duration.

299 With the rise in VRE infections, clinicians are increasingly reliant on reserved antibiotic therapies 300 such as daptomycin and linezolid as the backbone of successful treatment. By deploying whole-genome 301 sequencing in a series of DLVRE isolates separated by 13 weeks, we were able to determine genetic 302 explanations for the observed vancomycin, daptomycin and linezolid resistant phenotypes in our isolates. 303 Our work, in conjunction with others, demonstrates the utility of whole-genome sequencing longitudinal 304 samples during prolonged infection to map genomic changes responsible for acquired AMR (17, 22). 305 Given the observation that there was plasmid heterogeneity in p3 between Isolates 3 and 5 and Isolate 4, 306 our also work suggests that there are likely subpopulations of Efm that develop during protracted

307 infection. Plasmid 3 was virtually identical in Isolates 3 and 5, which are separated by 96 days, but was 308 missing a substantial segment in Isolate 4 which was isolated temporally between Isolates 3 and 5. The 309 idea of a single species bacterial "cloud of diversity" in prolonged infection is not new, but the impact of 310 this diversity on successful antimicrobial treatment and infection outcome is clinically underappreciated (4, 51, 52). We have shown that subpopulations may possess different armamentariums of AMR genes 311 312 and vary in degree of resistance. These observations are missed by traditional methods of AMR detection, 313 making targeted treatment decisions based on such methods problematic. Phenotypic resistance analysis 314 from an isolated colony may mask small subpopulations that harbor more difficult-to-treat antimicrobial 315 resistant phenotypes and lead to suboptimal antimicrobial therapy decisions. 316 With the increasing rates of MDR *Efm* infections, it is critical that we understand how *Efm* adapts 317 to prolonged antimicrobial pressure and recognize that traditional clinical resistance testing may not 318 mirror population level AMR phenotypes. Further work is needed to elucidate the best course of 319 treatment for patients with VRE requiring long-term antibiotic therapy and for those who develop MDR

Efm while on therapy (24). Synergy testing is currently not available in most clinical laboratories. Our study highlights the urgent need for rapid implementation of investigational MIC testing paired with genomic analysis to successfully support real-time clinical decision making.

323 ACKNOWLEDGMENTS

324 This work was supported by grants from the National Institutes of Health (NIH)/National Institute of 325 General Medical Sciences (NIGMS) (T32 GM008152 awarded to N.B.P), an American Cancer Society (ACS) 326 Clinician Scientist Development Grant (#134251-CSDG-20-053-01-MPC, awarded to K.E.R.B.), and a 327 Northwestern University Emerging and Re-emerging Pathogen Program (EREPP) grant (awarded to 328 K.E.R.B.). This work was also supported by the Northwestern Memorial Clinical Microbiology laboratory 329 and the NUSeq Core Facility which is generously supported by the NCI CCSG P30 CA060553 award to the 330 Robert H. Lurie Comprehensive Cancer Center. This work was supported in part through the 331 computational resources and staff contributions provided by the Genomics Compute Cluster which is 332 jointly supported by the Feinberg School of Medicine, the Center for Genetic Medicine, and Feinberg's 333 Department of Biochemistry and Molecular Genetics, the Office of the Provost, the Office for Research, and Northwestern Information Technology. The Genomics Compute Cluster is part of Quest, 334 335 Northwestern University's high-performance computing facility, with the purpose to advance research in 336 genomics. The funders had no role in study design, data collection and analysis, decision to publish, or 337 preparation of the manuscript. We would like to thank members of the Hauser and Ozer laboratories for 338 their valuable comments during numerous discussions of this work.

339

341 FIGURES and TABLES



FIGURE 1 Timeline of antimicrobial treatment and *E. faecium* isolate recovery. Post-operative day and *Efm* isolate recovery profiles (V, vancomycin; L, linezolid, D, daptomycin; bottom) are shown together with antibiotic and antifungal treatment regimens. Vancomycin-resistant enterococci (VRE) targeted antimicrobials are highlighted in orange and other antimicrobials are presented in light grey. Isolate post-operative day recovery dates are highlighted in blue. Inverted carrots signify that the antimicrobial agent in question was continued throughout the time period in question. Two vertical forward slashes denote time breaks.



352

FIGURE 2 Synergy susceptibility testing of *Efm* Isolate 3. (A) DAP E-test of isolate 3 (16 μ g/mL). (B) Combination E-testing of DAP and CPT of Isolate 3 (DAP MIC 12 μ g/mL). Synergy was tested by first applying a DAP E-test to the plate, removing it, applying a CPT E-test on the exact same location, and placing the DAP E-test directly on top to read the susceptibility to DAP in the presence of CPT.



358

359 FIGURE 3 Alignment of plasmid 3 from Isolates 4 and 5 to the vancomycin resistance plasmid 3 of

- **Isolate 3.** Regions present in Isolate 4 and 5 draft genomes are indicated in purple and green
- 361 respectively. Identified resistance genes are indicated in black.

Antibiotic	Isolate 1	Isolate 2	Isolate 3 ^b	Isolate 4 ^b	Isolate 5 ^b
	(VRE)	(LVRE)	(DLVRE)	(DLVRE)	(DLVRE)
Ampicillin	≥32 R	≥32 R	≥32 R	≥32 R	≥32 R
Daptomycin		2 SDD	12 R ^a	16 R ^a	16 R ^a
Linezolid	2 S	128 R ^a	48 R ^a	>256 R ^a	12 R ^a
Vancomycin	≥32 R	≥32 R	≥32 R	≥32 R	≥32 R

363 **TABLE 1** Minimal Inhibitory Concentrations (MICs μg/mL) for the patient's isolates of *Efm*

364 R, resistant; S, susceptible; SDD, susceptible dose dependent; --, not reported.

365 ^aMICs determined by E-testing assays.

366 ^bSequenced isolate.

369 **TABLE 2** Genomic mechanisms of antimicrobial resistance identified in Isolates 3, 4, and 5.

Antibiotic	Resistance Determinants	Location in Isolate 3	Isolate 3	Isolate 4	Isolate 5	
Ampicillin	<i>pbp5</i> (Val24Ala, Ser27Gly, Arg34Gln, Gly66Glu, Ala68Thr, Glu85Asp, Glu100Gln, Lys144Gln, Thr172Ala, Leu177Ile, Asp204Gly, Ala216Ser, Thr324Ala, Met485Ala, Asn496Lys, Ala499Thr, Glu525Asp, Glu629Val, Pro667S)	Chromosome	÷	+	+	
Linezolid	23S rRNA gene G2576T	Chromosome	3/6 copies	3/6 copies	2/6 copies	
	<i>liαS (</i> Thr120Ala)	Chromosome	+	+	+	
Daptomycin	liaR (Trp73Cys)	Chromosome	+	+	+	
	cls (Asp13lle)	Chromosome	+	+	+	
	vanHAX	Plasmid 3	+	+	+	
Vancomycin	vanSR	Plasmid 3	+	+	+	
	vanZY	Plasmid 3	+	+	+	
Fluoroquinolones	<i>gyrA</i> (Ser83Tyr)	Chromosome	+	+	+	
	parC (Ser80Arg)	Chromosome	+	+	+	
	aac(6′)-I	Chromosome	+	+	+	
Aminoglycosides	aph(3')-Illa	Plasmid 3	+	-	+	
	ant(6)-la	Plasmid 3	+	-	+	
Trimethoprim	dfrF	Chromosome	+	+	+	
	dfrG	Chromosome	+	+	+	
	tetL	Chromosome	+	+	+	
Tetracyclines	tetM	Chromosome	partial and complete copy	partial copy	partial copy	
Streptothricin	sat4	Plasmid 3	+	-	+	
Macrolides	msrC	Chromosome	+	+	+	
	ermB	Plasmid 3	+	-	+	

371 SUPPLEMENTARY TABLE S1 Characterization of Isolate 3 plasmids.

			Representative Similar Plasmid ^a					
Plasmid	Length (bp)	Replicon	GenBank Accession	Length	Query Coverage (%)	Query Identity (%)	PMID Reference	
1	228311	repUS15	CP064425.1	203164	80	99.96	33332354	
2	59066	unknown	CP012468.1	84196	92	100	28301471	
3	40605	rep17	CP076330.1	40559	95	99.87	34747439	
4	11983	rep29	CP065776.1	27166	99	99.16	33895846	
5	1928	rep14a (partial)	CP064442.1	1928	100	100	33332354	

372 ^aBased on BLAST search against *Enterococcus* sequences in the NCBI nt database

374 SUPPLEMENTARY TABLE S2 Alignment of Isolate 4 and 5 to the Isolate 3 Complete Genome.

	Chromosome		p1		p2		р3		p4		р5	
Isolate	Percent Alignment ^a	SNVs										
4	95.0	2	98.7	0	100	0	78.3	0	90.0	0	100	0
5	96.1	13	99.1	3	100	0	98.9	0	92.5	0	100	0

³⁷⁵ ^aPercentage of total length of covered by aligned sequences with a minimum depth cutoff of 5 reads.

376 SUPPLEMENTARY TABLE S3 SNVs Detected in Alignment of Isolate 4 and 5 to the Isolate 3 Complete

377 Genome

Location	Site	Annotation in Isolate 3	Isolate 4	Isolate 5
Chromosome	89200	intergenic	-	+
Chromosome	232118	cation-translocating P-type ATPase	-	+
Chromosome	413477	intergenic	+	+
Chromosome	1016951	cardiolipin synthase	-	+
Chromosome	1125507	NAD(P)/FAD-dependent oxidoreductase	-	+
Chromosome	1208228	rsmD	-	+
Chromosome	1263527	branched-chain amino acid aminotransferase	-	+
Chromosome	1342358	ABC transporter substrate- binding protein	-	+
Chromosome	1887988	intergenic	+	+
Chromosome	1896892	Xaa-Pro peptidase family protein	-	+
Chromosome	2107572	alpha/beta fold hydrolase	-	+
Chromosome	2547067	intergenic	-	+
Chromosome	2720433	pseudogene	-	+
p1	167	repA	-	+
p1	120818	HAMP domain-containing histidine kinase	-	+
p1	177993	Heavy metal translocating P-type ATPase	-	+

378

379

380

383 **REFERENCES**

- Arias CA, Murray BE. 2012. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev
 Microbiol 10:266-78.
- 386 2. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM. 2016.
- 387 Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary
- of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control
 and Prevention, 2011-2014. Infect Control Hosp Epidemiol 37:1288-1301.
- Fisher K, Phillips C. 2009. The ecology, epidemiology and virulence of Enterococcus. Microbiology
 (Reading) 155:1749-1757.
- 392 4. Dubin KA, Mathur D, McKenney PT, Taylor BP, Littmann ER, Peled JU, van den Brink MRM, Taur Y,
- Pamer EG, Xavier JB. 2019. Diversification and Evolution of Vancomycin-Resistant *Enterococcus faecium* during Intestinal Domination. Infect Immun 87.
- 395 5. Paulsen IT, Banerjei L, Myers GS, Nelson KE, Seshadri R, Read TD, Fouts DE, Eisen JA, Gill SR,
- 396 Heidelberg JF, Tettelin H, Dodson RJ, Umayam L, Brinkac L, Beanan M, Daugherty S, DeBoy RT,
- 397 Durkin S, Kolonay J, Madupu R, Nelson W, Vamathevan J, Tran B, Upton J, Hansen T, Shetty J,
- 398 Khouri H, Utterback T, Radune D, Ketchum KA, Dougherty BA, Fraser CM. 2003. Role of mobile
- 399 DNA in the evolution of vancomycin-resistant *Enterococcus faecalis*. Science 299:2071-4.
- Garcia-Solache M, Rice LB. 2019. The Enterococcus: a Model of Adaptability to Its Environment.
 Clin Microbiol Rev 32.
- Poeta P, Costa D, Igrejas G, Sáenz Y, Zarazaga M, Rodrigues J, Torres C. 2007. Polymorphisms of
 the pbp5 gene and correlation with ampicillin resistance in *Enterococcus faecium* isolates of
 animal origin. J Med Microbiol 56:236-240.

- 405 8. Fontana R, Aldegheri M, Ligozzi M, Lopez H, Sucari A, Satta G. 1994. Overproduction of a low-
- 406 affinity penicillin-binding protein and high-level ampicillin resistance in *Enterococcus faecium*.
- 407 Antimicrob Agents Chemother 38:1980-3.
- 408 9. Galloway-Pena JR, Rice LB, Murray BE. 2011. Analysis of PBP5 of early U.S. isolates of *Enterococcus*
- 409 *faecium*: sequence variation alone does not explain increasing ampicillin resistance over time.
- 410 Antimicrob Agents Chemother 55:3272-7.
- 411 10. Pietta E, Montealegre MC, Roh JH, Cocconcelli PS, Murray BE. 2014. Enterococcus faecium PBP5-
- 412 S/R, the missing link between PBP5-S and PBP5-R. Antimicrob Agents Chemother 58:6978-81.
- 413 11. Ahmed MO, Baptiste KE. 2018. Vancomycin-Resistant Enterococci: A Review of Antimicrobial
- 414 Resistance Mechanisms and Perspectives of Human and Animal Health. Microb Drug Resist 415 24:590-606.
- 416 12. Arias CA, Contreras GA, Murray BE. 2010. Management of multidrug-resistant enterococcal
 417 infections. Clin Microbiol Infect 16:555-62.
- 418 13. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad, II, Rijnders BJ, Sherertz RJ,
- 419 Warren DK. 2009. Clinical practice guidelines for the diagnosis and management of intravascular
- 420 catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect421 Dis 49:1-45.
- 422 14. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. 2011. Daptomycin nonsusceptible enterococci: an
 423 emerging challenge for clinicians. Clin Infect Dis 52:228-34.
- 424 15. Bi R, Qin T, Fan W, Ma P, Gu B. 2018. The emerging problem of linezolid-resistant enterococci. J
 425 Glob Antimicrob Resist 13:11-19.
- 426 16. Arias CA, Murray BE. 2008. Emergence and management of drug-resistant enterococcal
 427 infections. Expert Rev Anti Infect Ther 6:637-55.

- 428 17. Chacko KI, Sullivan MJ, Beckford C, Altman DR, Ciferri B, Pak TR, Sebra R, Kasarskis A, Hamula CL,
- 429 van Bakel H. 2018. Genetic Basis of Emerging Vancomycin, Linezolid, and Daptomycin 430 Heteroresistance in a Case of Persistent Bacteremia. Antimicrob Agents Chemother 62.
- 431 Klare I, Fleige C, Geringer U, Thurmer A, Bender J, Mutters NT, Mischnik A, Werner G. 2015. 18.
- Increased frequency of linezolid resistance among clinical Enterococcus faecium isolates from 432 433 German hospital patients. J Glob Antimicrob Resist 3:128-131.
- 434 19. Kamboj M, Cohen N, Gilhuley K, Babady NE, Seo SK, Sepkowitz KA. 2011. Emergence of 435 daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol 436 32:391-4.
- Bender JK, Cattoir V, Hegstad K, Sadowy E, Coque TM, Westh H, Hammerum AM, Schaffer K, Burns 437 20. 438 K, Murchan S, Novais C, Freitas AR, Peixe L, Del Grosso M, Pantosti A, Werner G. 2018. Update on 439 prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature. Drug Resist Updat 40:25-39.
- 440
- 441 21. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, Tran TT, Rincon S, Barbu EM,
- 442 Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn JP, Shamoo Y, Murray BE,
- Weinstock GM. 2011. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 443 365:892-900. 444
- 445 22. Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, Diaz L, Lobos EA, Shamoo Y, Mishra NN, 446 Bayer AS, Murray BE, Weinstock GM, Arias CA. 2013. Whole-genome analysis of a daptomycinsusceptible Enterococcus faecium strain and its daptomycin-resistant variant arising during 447 therapy. Antimicrob Agents Chemother 57:261-8. 448
- Greene MH, Harris BD, Nesbitt WJ, Watson ML, Wright PW, Talbot TR, Nelson GE. 2018. Risk 449 23. 450 Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible 451 Vancomycin-Resistant Enterococcus. Open Forum Infect Dis 5:ofy185.

- 452 24. Contreras GA, Munita JM, Simar S, Luterbach C, Dinh AQ, Rydell K, Sahasrabhojane PV, Rios R,
 453 Diaz L, Reyes K, Zervos M, Misikir HM, Sanchez-Petitto G, Liu C, Doi Y, Abbo LM, Shimose L, Seifert
 454 H, Gudiol C, Barberis F, Pedroza C, Aitken SL, Shelburne SA, van Duin D, Tran TT, Hanson BM, Arias
 455 CA. 2022. Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant
 456 Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I). Open Forum Infect
 457 Dis 9:ofab616.
- Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphries R, Nizet V. 2014. Ceftaroline
 restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant
 Enterococcus faecium. Antimicrob Agents Chemother 58:1494-500.
- Sakoulas G, Nonejuie P, Nizet V, Pogliano J, Crum-Cianflone N, Haddad F. 2013. Treatment of highlevel gentamicin-resistant *Enterococcus faecalis* endocarditis with daptomycin plus ceftaroline.
 Antimicrob Agents Chemother 57:4042-5.
- Chuang YC, Chen PY, Lin CY, Chen YC, Wang JT, Chang SC. 2018. A retrospective clinical comparison
 of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant
 Enterococcus faecium bloodstream infections. Sci Rep 8:1632.
- 467 28. Jahanbakhsh S, Singh NB, Yim J, Kebriaei R, Smith JR, Lev K, Tran TT, Rose WE, Arias CA, Rybak MJ.
- 2020. Impact of Daptomycin Dose Exposure Alone or in Combination with beta-Lactams or
 Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model. Antimicrob
 Agents Chemother 64.
- 471 29. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA.
- 472 2012. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of
 473 ampicillin- and vancomycin-resistant *Enterococcus faecium*. Antimicrob Agents Chemother
 474 56:838-44.

- 30. Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ. 2015. beta-Lactam combinations
 with daptomycin provide synergy against vancomycin-resistant *Enterococcus faecalis* and *Enterococcus faecium*. J Antimicrob Chemother 70:1738-43.
- 478 31. Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A. 2017. Ceftazidime-Avibactam and
- 479 Aztreonam, an Interesting Strategy To Overcome beta-Lactam Resistance Conferred by Metallo-
- 480 beta-Lactamases in Enterobacteriaceae and *Pseudomonas aeruginosa*. Antimicrob Agents 481 Chemother 61.
- 482 32. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data.
 483 Bioinformatics 30:2114-20.
- Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: Resolving bacterial genome assemblies
 from short and long sequencing reads. PLoS Comput Biol 13:e1005595.
- Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, Lomsadze A, Pruitt
 KD, Borodovsky M, Ostell J. 2016. NCBI prokaryotic genome annotation pipeline. Nucleic Acids
 Res 44:6614-24.
- 489 35. Jolley KA, Bray JE, Maiden MCJ. 2018. Open-access bacterial population genomics: BIGSdb
 490 software, the PubMLST.org website and their applications. Wellcome Open Res 3:124.
- 491 36. Carattoli A, Zankari E, Garcia-Fernandez A, Voldby Larsen M, Lund O, Villa L, Moller Aarestrup F,
- Hasman H. 2014. In silico detection and typing of plasmids using PlasmidFinder and plasmid
 multilocus sequence typing. Antimicrob Agents Chemother 58:3895-903.
- 494 37. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham
- 495 S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012.
- 496 SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J 497 Comput Biol 19:455-77.

Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH, Zhao S, Hsu CH,
McDermott PF, Tadesse DA, Morales C, Simmons M, Tillman G, Wasilenko J, Folster JP, Klimke W.
2019. Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial
Resistance Genotype-Phenotype Correlations in a Collection of Isolates. Antimicrob Agents
Chemother 63.

- 39. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL, Rebelo
 AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK, Stingl K, Nguyen
 M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum MF, Duggett NA, Kempf
 I, Nykasenoja S, Olkkola S, Wieczorek K, Amaro A, Clemente L, Mossong J, Losch S, Ragimbeau C,
 Lund O, Aarestrup FM. 2020. ResFinder 4.0 for predictions of phenotypes from genotypes. J
- 508 Antimicrob Chemother 75:3491-3500.
- 509 40. Hasman H, Clausen P, Kaya H, Hansen F, Knudsen JD, Wang M, Holzknecht BJ, Samulioniene J,
- 510 Roder BL, Frimodt-Moller N, Lund O, Hammerum AM. 2019. LRE-Finder, a Web tool for detection
- 511 of the 23S rRNA mutations and the optrA, cfr, cfr(B) and poxtA genes encoding linezolid resistance
- 512 in enterococci from whole-genome sequences. J Antimicrob Chemother 74:1473-1476.
- 41. Pincus NB, Bachta KER, Ozer EA, Allen JP, Pura ON, Qi C, Rhodes NJ, Marty FM, Pandit A,
 514 Mekalanos JJ, Oliver A, Hauser AR. 2020. Long-term Persistence of an Extensively Drug-Resistant
 515 Subclade of Globally Distributed *Pseudomonas aeruginosa* Clonal Complex 446 in an Academic
 516 Medical Center. Clin Infect Dis 71:1524-1531.
- 517 42. Li H. 2011. A statistical framework for SNP calling, mutation discovery, association mapping and 518 population genetical parameter estimation from sequencing data. Bioinformatics 27:2987-93.
- Alikhan NF, Petty NK, Ben Zakour NL, Beatson SA. 2011. BLAST Ring Image Generator (BRIG):
 simple prokaryote genome comparisons. BMC Genomics 12:402.

- 44. Anonymous. 2021. Performance standards for antimicrobial susceptibility testing: 31st
 informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
- 523 45. Top J, Willems R, Bonten M. 2008. Emergence of CC17 Enterococcus faecium: from commensal to
- 524 hospital-adapted pathogen. FEMS Immunol Med Microbiol 52:297-308.
- 46. Top J, Willems R, van der Velden S, Asbroek M, Bonten M. 2008. Emergence of clonal complex 17
- 526 *Enterococcus faecium* in The Netherlands. J Clin Microbiol 46:214-9.
- 47. Lee T, Pang S, Abraham S, Coombs GW. 2019. Antimicrobial-resistant CC17 *Enterococcus faecium*:
- 528 The past, the present and the future. J Glob Antimicrob Resist 16:36-47.
- 529 48. Arredondo-Alonso S, Top J, McNally A, Puranen S, Pesonen M, Pensar J, Marttinen P, Braat JC,
- 530 Rogers MRC, van Schaik W, Kaski S, Willems RJL, Corander J, Schurch AC. 2020. Plasmids Shaped
- the Recent Emergence of the Major Nosocomial Pathogen *Enterococcus faecium*. mBio 11.
- 49. Wardal E, Kuch A, Gawryszewska I, Zabicka D, Hryniewicz W, Sadowy E. 2017. Diversity of plasmids
- and Tn1546-type transposons among VanA *Enterococcus faecium* in Poland. Eur J Clin Microbiol
 Infect Dis 36:313-328.
- 535 50. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. 2002. Gene dosage and linezolid 536 resistance in *Enterococcus faecium* and *Enterococcus faecalis*. Antimicrob Agents Chemother 537 46:3334-6.
- 51. Chilambi GS, Nordstrom HR, Evans DR, Ferrolino JA, Hayden RT, Maron GM, Vo AN, Gilmore MS,
 Wolf J, Rosch JW, Van Tyne D. 2020. Evolution of vancomycin-resistant *Enterococcus faecium*during colonization and infection in immunocompromised pediatric patients. Proc Natl Acad Sci
- 541 U S A 117:11703-11714.
- 542 52. Williams D, Evans B, Haldenby S, Walshaw MJ, Brockhurst MA, Winstanley C, Paterson S. 2015.
- 543 Divergent, coexisting *Pseudomonas aeruginosa* lineages in chronic cystic fibrosis lung infections.
- 544 Am J Respir Crit Care Med 191:775-85.